Log In
BCIQ
Print this Print this
 

elvucitabine (ACH-126, ACH-443, beta-L-Fd4C)

  Manage Alerts
Collapse Summary General Information
Company Achillion Pharmaceuticals Inc.
DescriptionL-cytosine nucleoside analog reverse transcriptase inhibitor
Molecular Target Viral polymerase
Mechanism of ActionNucleoside analog reverse transcriptase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV/AIDS
Regulatory Designation
PartnerGCA Therapeutics Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/08/2010

Undisclosed

0

Undisclosed

Get a free BioCentury trial today